E-3-[3’-(1-adamantyl)-2-chloro-4’-hydroxybiphenyl-4-yl]acrylic acid | 524937-17-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: E-3-[3’-(1-adamantyl)-2-chloro-4’-hydroxybiphenyl-4-yl]acrylic acid
• 英文别名: 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid；(E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid；3-CI-AHPC；MM002；E-3-[3'-(1-adamantyl)-2-chloro-4'-hydroxybiphenyl-4-yl]-acrylic acid；3-Cl-AHPC；(E)-3-[4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorophenyl]prop-2-enoic acid
• CAS: 524937-17-5
• 化学式: C₂₅H₂₅ClO₃
• 分子量: 408.925
• InChiKey: ZUIMAMHUQKPCBR-QHHAFSJGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  E-3-[3’-(1-adamantyl)-2-chloro-4’-hydroxybiphenyl-4-yl]acrylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 盐酸羟胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.53h， 生成 3-(3'-adamantan-1-yl-2-chloro-4'-hydroxybiphenyl-4-yl)-N-hydroxyacrylamide
  参考文献：
  名称：

  WO2007/383

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl E-(3-chloro-4-hydroxyphenyl)acrylate 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 lithium hydroxide monohydrate 、 potassium acetate 、 三乙胺 、 联硼酸频那醇酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 15.0h， 生成 E-3-[3’-(1-adamantyl)-2-chloro-4’-hydroxybiphenyl-4-yl]acrylic acid
  参考文献：
  名称：

  Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors

  摘要：

  To investigate the influence of the adamantyl group on the biological properties of known HDAC inhibitors with a 4-phenylcinnamic skeleton, a series of compounds having the adamantyl moiety in the cap structure were synthesized and compared to the corresponding hydroxamic acids lacking this group. An unexpected finding was the substantial reduction of inhibitory activity toward the tested enzymes, in particular HDAC6, following the introduction of the adamantyl group. In spite of the reduced ability to function as HDAC inhibitors, the compounds containing the adamantyl moiety still retained a good efficacy as antiproliferative and proapoptotic agents. A selected compound (2c; ST3056) of this series exhibited an appreciable antitumor activity against the colon carcinoma xenograft HCT116. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.021

文献信息

• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV WAYNE STATE

  公开号：WO2011079305A1

  公开（公告）日：2011-06-30

  The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.

  该发明提供了如下所述的式I化合物或其盐。该发明还提供了包括式I化合物的药物组合物，制备式I化合物的方法，用于制备式I化合物的有用中间体以及利用式I化合物诱导凋亡或治疗癌症的治疗方法。
• [EN] NEW RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES<br/>[FR] NOUVEAUX DÉRIVÉS DE RÉTINOÏDES PRÉSENTANT DES PROPRIÉTÉS CYTOTOXIQUES ET/OU ANTI-ANGIOGÈNES
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2010072727A1

  公开（公告）日：2010-07-01

  The present invention relates to new retinoid derivatives of Formula (I), and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumours, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.

  本发明涉及公式(I)的新视黄醇衍生物，以及含有它们的药物组合物，用于治疗患有关节炎、肿瘤、转移性癌症、糖尿病性视网膜病变、银屑病、慢性炎症性疾病或动脉粥样硬化等病症的患者。
• Induction of apoptosis in cancer cells
  申请人：——

  公开号：US20030176506A1

  公开（公告）日：2003-09-18

  The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.

  本发明提供了诱导或抑制凋亡或在细胞周期停滞之前发生的凋亡的化合物。此外，本发明提供了用于治疗患有白血病或其他形式癌症的哺乳动物或治疗由细胞凋亡引起的疾病状况的药物组合物和方法。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• METHOD FOR PREPARTION OF SUBSTITUTED ADAMANTYLARYMAGNESIUM HALIDES
  申请人：Kalvinsh Ivars

  公开号：US20100113816A1

  公开（公告）日：2010-05-06

  The present invention concerns fine organic synthesis, particularly the method for preparing of substituted adamantylarylmagnesium halides. The known methods for preparing Grignard's reagent from substituted adamantylarylhalide give very low yeld of the desired product. Substituted adamantylarylhalides are active intermediates that by interacting with various electrophiles provide for a wide range of biologically active compounds. The aim of current invention was to develop a method for preparing substituted adamantylarylmagnesium halides. The aim was attained adding lithium chloride in the Grignard's reagent synthesis by acting on is magnesium metal in dry tetrahydrofuran under argon by substituted adamantylarylhalide. It was demonstrated that adding lithium chloride to adamantylarylhalide within a range from 1:1 to 1:2 provides for stable high yield of the desired end product.

  本发明涉及精细有机合成，特别是制备取代的金刚烷基芳基镁卤化物的方法。已知从取代的金刚烷基芳基卤化物制备格氏试剂的方法产生所需产品的收率非常低。取代的金刚烷基芳基卤化物是活性中间体，通过与各种亲电体相互作用，提供了广泛的生物活性化合物。本发明的目的是开发一种制备取代的金刚烷基芳基镁卤化物的方法。通过在干燥的四氢呋喃中作用于取代的金刚烷基芳基卤化物的格氏试剂合成中加入氯化锂，从而实现了这一目的。实验证明，在金刚烷基芳基卤化物中添加氯化锂，比例范围为1:1到1:2，可以提供稳定的高产率所需的最终产品。